Jennifer Rumpel, MD
Allergy & Immunology · Portage, INNPI 1588827562
Payments from drug & device makers
Across 838 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Optinose US, Inc.$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$1K
- Alk-abello, Inc$897
- plus $5K from 32 others
What the payments were for
- Consulting fees$530%
- Food & beverage$13,89098%
- Education$1611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 112 | $2,125 |
| Optinose US, Inc. | 128 | $1,584 |
| GSK | 127 | $1,571 |
| Regeneron Healthcare Solutions, Inc. | 74 | $1,386 |
| Sanofi | 55 | $1,292 |
| Alk-abello, Inc | 53 | $897 |
| Novartis | 48 | $755 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $735 |
| CSL Behring | 29 | $494 |
| Grifols USA, LLC | 25 | $448 |
| Amgen(2 entities) | 21 | $423 |
| Pharming Healthcare, Inc. | 13 | $287 |
| Biocryst US Sales Co., LLC | 13 | $261 |
| Pfizer | 11 | $213 |
| Genentech USA, Inc. | 10 | $206 |
| Kaleo, Inc. | 9 | $181 |
| Boehringer Ingelheim | 7 | $166 |
| Ionis Pharmaceuticals, Inc. | 8 | $159 |
| AbbVie | 7 | $131 |
| Lilly USA, LLC | 5 | $123 |
| LEO Pharma Inc. | 5 | $85 |
| Galderma Laboratories, L.p. | 2 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Octapharma USA, Inc. | 2 | $64 |
| Hospira, Inc. | 3 | $54 |
| ADMA Biomanufacturing LLC | 4 | $53 |
| Aimmune Therapeutics, Inc. | 3 | $42 |
| Shire North American Group Inc | 2 | $38 |
| Bio Products Laboratory USA, Inc. | 2 | $31 |
| Merck | 2 | $29 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| USWM, LLC | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 3 | $19 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
| Greer Laboratories, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,104 in reported general payments places this provider in the 70th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 42 | $177,050 |
| NucalaMepolizumab | 34 | $124,411 |
| XolairOmalizumab | 33 | $96,918 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $90,851 |
| Dupixent SyringeDupilumab | 13 | $67,323 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $36,937 |
| Advair HfaFluticasone Propion/Salmeterol | 44 | $19,714 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $16,636 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $14,685 |
| XhanceFluticasone Propionate | 11 | $6,780 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,226 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $5,011 |
| Epinephrine | 23 | $4,699 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $4,407 |
| Mometasone Furoate | 41 | $2,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,125 | $197,96188 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,571 | $177,984114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $735 | $90,85113 claims |
| Optinose US, Inc.Xhance | $1,584 | $6,78011 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $4,69923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Portage
- James HarrisSouth Bend$1.7M
- Nabeel FarooquiFishers$1.3M
- Majed KoleilatEvansville$713K
- Mitchell SmithGreenwood$425K
- Anne McLaughlinEvansville$380K
- David PattersonNoblesville$254K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Sohaib AleemSouth Bend$98K
- Pinkus GoldbergIndianapolis$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.